/ /

  • linkedin
  • Increase Font
  • Sharebar

    What you need to know about the Essilor-Luxottica deal

    Paris—In a $49 billion deal, Italian frames manufacturer Luxottica and French lens manufacturer Essilor formed a holding company, EssilorLuxottica, that will be co-run by both groups.

    “Each company will remain separate and operate as independent companies,” says Optometry Times Advisory Board and Essilor Advisory Board member John Rumpakis, OD, MBA. “But when the deal closes later this year and over the next three years, they will be taking a look at synergies where they can integrate and work together.”                                                                                                                            

    Powerhouses combine

    In its announcement, EssilorLuxottica said it will have more than 140,000 combined employees and sales in more than 150 countries. And based on the companies’ 2015 results, the new company would have posted a combined net revenue of nearly $16 billion. The company expects to have $424 million to $636 million in cost synergies after the deal is completed.

    In addition to being leaders in the lens and frame markets, respectively, each company also owns a variety of other big eyecare players.

    Related: ECPs unimpressed with Macys-Luxottica deal

    Some Essilor brands and subsidiaries include:

    • Vision Source

    • Transitions

    • Costa

    • Kodak Lens

    Professional Eyecare Resource Co-Operative (PERC)

    Some Luxottica brands and subsidiaries include:

    • EyeMed

    • LensCrafters

    • Pearle Vision

    • Sunglass Hut

    • Target Optical

    • Sears Optical

    • Glasses.com

    Related: Profiting with vision care plans

    Colleen E. McCarthy
    Colleen McCarthy is a freelance writer based in the Cleveland area and a former editor of Optometry Times. She is a 2010 graduate of the ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Optometry Times A/V